10th IAS Conference on HIV Science | 21-24 July 2019 | Mexico City, Mexico
 

News

Programme highlights: HIV treatment and cure science

posted on

29 May 2019 (Geneva, Switzerland) – The 10th IAS Conference on HIV Science (IAS 2019) will showcase many exciting advances in HIV treatment strategies and the search for a cure, with a significant focus on moving scientific knowledge into policy and practice. Take a look at some of the abstracts, plenary talks, and sessions that will highlight these topics at the conference.

Scientific highlights

Examples of abstracts related to HIV treatment and cure science include:

  • Insights from a “mystery shopper” study in Kenya assessing the experiences of young adults seeking to buy HIV self-test kits
  • New data from the ATLAS study of a long-acting injectable two-drug regimen for the treatment of HIV
  • Latest findings on the safety and efficacy of switching to a single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF)
  • Results of a large cohort study of renal function trajectories after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF)
  • Progress toward a functional cure, including new data on the safety and activity of vesatolimod, a toll-like receptor 7 agonist, in people living with HIV
  • Important analysis of long-term outcomes for adolescents born with HIV in six African countries
  • Results from a study investigating interventions to increase viral suppression among transgender women in the US
  • Innovative technologies that could improve treatment delivery in developing countries, such as an ATM-style machine that dispenses medication and allows patients to communicate with tele-pharmacists
  • Updates on the potential link between dolutegravir (DTG) and neural tube birth defects.

Plenaries

Asa Radix

Scaling up treatment in resource-constrained settings: What will it take to achieve the last 90?
by Ingrid Bassett, Massachusetts General Hospital, United States

Adam Burgener

Barriers to access to diagnosis and treatment
by Adam Burgener, University of Manitoba

Carlos Fernando Caceres

Primary HIV infection: An opportunity not to be missed?
by John Frater, Oxford University, United Kingdom

Carlos Fernando Caceres

Co-morbidities
by Esteban Martínez, University of Barcelona, Spain

Carlos Fernando Caceres

Stem cell and genome editing for HIV cure
by Paula Cannon, University of Southern California, United States

Sessions

  • ART: Trials and tribulations
  • Same-day ART, one size fits all?
  • HIV and pregnancy, beyond Dolutegravir
  • Paediatric HIV infection: It's never too early
  • #RecognizeAndOptimize: Pediatrics and adolescent HIV
  • Pathogenesis: And the band plays on
  • Co-morbidities: No organ left behind
  • Deadly partners: HIV and co-infections
  • 50 shades of reservoirs
  • Mission remission: Challenge accepted
  • Achieving HIV control
  • Keep control: Elite and post-treatment controllers
  • Hide and seek: Reservoir and strategies to target them
  • What is the cure, why do we need it and how do we get there?

Media contact
Mandy Sugrue
Communications Director
[email protected]

Sign up for
IAS 2019 news